Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma

Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends

(2017) Sebastien Antoni et al.   EUROPEAN UROLOGY

Treatment patterns and economic burden of illness in patients with advanced bladder cancer receiving second-line therapy.

(2017) Sumati Rao et al.   JOURNAL OF CLINICAL ONCOLOGY

Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

(2017) Philippe E. Spiess et al.   Journal of the National Comprehensive Cancer Network

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

(2017) Arjun V Balar et al.   LANCET

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

(2017) Arjun V Balar et al.   LANCET ONCOLOGY

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

(2017) Padmanee Sharma et al.   LANCET ONCOLOGY

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives

(2017) Clizia Zichi et al.   Biomed Research International

Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions

(2017) Shilpa Gupta et al.   Cancers

Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer

(2016) Tracy L. Rose et al.   CANCER

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

(2016) Christophe Massard et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Comparison of SEER Treatment Data With Medicare Claims

(2016) Anne-Michelle Noone et al.   MEDICAL CARE

The treatment patterns, efficacy, and safety of nab®-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis

(2015) Caihua Liang et al.   BMC CANCER

Algorithm for Identifying Chemotherapy/Biological Regimens for Metastatic Colon Cancer in SEER-Medicare

(2015) Kaloyan A. Bikov et al.   MEDICAL CARE

The Health Economics of Bladder Cancer: An Updated Review of the Published Literature

(2014) Christina Yeung et al.   PHARMACOECONOMICS

First- and second-line therapy for metastatic urothelial carcinoma of the bladder

(2011) F. A. Yafi et al.   Current Oncology

Economic aspects of bladder cancer: what are the benefits and costs?

(2009) K. D. Sievert et al.   WORLD JOURNAL OF UROLOGY

The present and future burden of urinary bladder cancer in the world

(2009) Martine Ploeg et al.   WORLD JOURNAL OF UROLOGY

Clinical Model of Cost of Bladder Cancer in the Elderly

(2008) Catherine D. Cooksley et al.   UROLOGY